| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_03c4720e107878f494e6eb5a8e8500ea
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_355c8db7e8c8f57b21419313813d38cc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bacdffdb18b6ec7976d0489226a46301 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-524
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2896 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate |
2010-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9fd2007eaf6cbe3ba7eaffe3a1f5b442
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f8e88d7689f4254e454dd14da8877e6 |
| publicationDate |
2012-01-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2409993-A1 |
| titleOfInvention |
Anti-CD19 antibody having ADCC function with improved glycosylation profile |
| abstract |
The present invention relates to an anti-CD19 antibody having a variant Fc region having some specific amino acid modifications relative to a wild-type Fc region which confer one or several useful effector functions. The present invention relates in particular to chimeric, humanized or full human anti-CD19 antibodies comprising such a variant Fc region. It relates advantageously to antibodies with an interesting and valuable glycosylation profile, especially a low fucose level and/or a high oligomannose level and/or presence of sialic acid, high ADCC function and no CDC. The present invention also relates to the use of these antibodies in the treatment, prevention or management of diseases or disorders, such as cancer, especially a B-cell malignancy and auto-immune disease. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/IL-258332-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/IL-258332-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/IL-299203-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-I797065-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3362479-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2016339832-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107531793-A |
| priorityDate |
2010-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |